| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Research Support, Non-U.S. Gov't
- Language: English
- [Pancreas] 2022 Oct 01; Vol. 51 (9), pp. 1235-1247.
- MeSH Terms: Pancreatic Neoplasms* / pathology ; Carcinoma, Pancreatic Ductal* / pathology ; Humans ; Chemokines, CXC / genetics ; Prognosis ; Receptors, Cytokine ; Biomarkers, Tumor / genetics ; Tumor Microenvironment ; rho-Associated Kinases ; Pancreatic Neoplasms
- References: Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet . 2020;395:2008–2020. ; Arias-Pinilla GA, Modjtahedi H. Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities. Cancers (Basel) . 2021;13:1781. ; The Surveillance, Epidemiology, and End Results (SEER) Program. SEER Incidence Data, 1975–2018. Available at: https://seer.cancer.gov . Assessed March 8, 2021). ; Strobel O, Neoptolemos J, Jäger D, et al. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol . 2019;16:11–26. ; Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity . 2021;54:859–874. ; Yeo ECF, Brown MP, Gargett T, et al. The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cell . 2021;10:607. ; Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol . 2017;17:559–572. ; Mollica Poeta V, Massara M, Capucetti A, et al. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol . 2019;10:379. ; Korbecki J, Kojder K, Kapczuk P, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors—a review of literature. Int J Mol Sci . 2021;22:843. ; Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett . 2008;267:226–244. ; Lin C, He H, Liu H, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut . 2019;68:1764–1773. ; Fukuda Y, Asaoka T, Eguchi H, et al. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma. Cancer Sci . 2020;111:323–333. ; Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine . 2018;109:24–28. ; Gao Q, Wang S, Chen X, et al. Cancer-cell–secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer . 2019;7:42. ; Yin Z, Huang J, Ma T, et al. Macrophages activating chemokine (C-X-C motif) ligand 8/miR-17 cluster modulate hepatocellular carcinoma cell growth and metastasis. Am J Transl Res . 2017;9:2403–2411. ; Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res . 2017;45:W98–W102. ; Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia . 2004;6:1–6. ; Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia . 2017;19:649–658. ; Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal . 2013;6:pl1. ; Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res . 2010;38:W214–W220. ; Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res . 2019;47:D607–D613. ; Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc . 2009;4:44–57. ; Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun . 2019;10:1523. ; Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene . 2005;24:6626–6636. ; Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res . 2018;46:D380–D386. ; Li T, Fan J, Wang B, et al. TIMER: a Web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res . 2017;77:e108–e110. ; Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell . 2009;16:259–266. ; Badea L, Herlea V, Dima SO, et al. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology . 2008;55:2016–2027. ; Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res . 2003;63:2649–2657. ; Ishikawa M, Yoshida K, Yamashita Y, et al. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci . 2005;96:387–393. ; Segara D, Biankin AV, Kench JG, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res . 2005;11:3587–3596. ; Grützmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia . 2004;6:611–622. ; Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol . 2003;162:1151–1162. ; Rossi JF, Lu ZY, Massart C, et al. Dynamic immune/inflammation precision medicine: the good and the bad inflammation in infection and cancer. Front Immunol . 2021;12:595722. ; Nam GH, Choi Y, Kim GB, et al. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater . 2020;32:e2002440. ; Karin N. Chemokines and cancer: new immune checkpoints for cancer therapy. Curr Opin Immunol . 2018;51:140–145. ; Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers (Basel) . 2020;12:2984. ; Hill M, Segovia M, Russo S, et al. The paradoxical roles of inflammation during PD-1 blockade in cancer. Trends Immunol . 2020;41:982–993. ; Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: a cross talk. Front Immunol . 2018;9:563. ; Lundgren S, Elebro J, Heby M, et al. Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. Int J Cancer . 2020;146:3461–3473. ; Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med . 2020;26:878–885. ; Westrich JA, Vermeer DW, Colbert PL, et al. The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses. Mol Carcinog . 2020;59:794–806. ; Allaoui R, Bergenfelz C, Mohlin S, et al. Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun . 2016;7:13050. ; Kim MJ, Sun HJ, Song YS, et al. CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. Sci Rep . 2019;9:13288. ; MacGregor HL, Garcia-Batres C, Sayad A, et al. Tumor cell expression of B7–H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. Oncoimmunology . 2019;8:e1665460.
- Substance Nomenclature: 0 (Chemokines, CXC) ; 0 (Receptors, Cytokine) ; 0 (Biomarkers, Tumor) ; EC 2.7.11.1 (ROCK1 protein, human) ; EC 2.7.11.1 (rho-Associated Kinases)
- Entry Date(s): Date Created: 20230420 Date Completed: 20230424 Latest Revision: 20231213
- Update Code: 20240513
|
